SCHEMBL22909774

SCHEMBL22909774

COC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc1csc2ccc(Cl)cc12)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 1/20 0.41
NOS3 P29474 3/20 0.39
NOS1 P29475 3/20 0.39
NOS2 P35228 3/20 0.39
AAK1 Q2M2I8 2/20 0.39
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36
PSEN1 P49768 2/20 0.35
PSEN2 P49810 2/20 0.35
APH1B Q8WW43 2/20 0.35
NCSTN Q92542 2/20 0.35
APH1A Q96BI3 2/20 0.35
PSENEN Q9NZ42 2/20 0.35
TAS1R3 Q7RTX0 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22909904 0.92 REN (0.41) RENAAK1KEAP1NFE2L2CTSL
SCHEMBL21411582 0.92 REN (0.41) RENAAK1KEAP1NFE2L2CTSL
SCHEMBL21411585 0.92 REN (0.41) RENAAK1KEAP1NFE2L2CTSL
SCHEMBL21431089 0.81 KEAP1 (0.50) KEAP1NFE2L2CTSLCTSSCTSK
SCHEMBL21411560 0.81 KEAP1 (0.50) KEAP1NFE2L2CTSLCTSSCTSK
SCHEMBL21411564 0.81 KEAP1 (0.50) KEAP1NFE2L2CTSLCTSSCTSK
SCHEMBL21411566 0.77 PTPN1 (0.39) KEAP1NFE2L2MMP2MMP9MMP8
SCHEMBL21411567 0.77 PTPN1 (0.39) KEAP1NFE2L2MMP2MMP9MMP8
SCHEMBL13030665 0.75 AAK1 (0.48) RENAAK1CTSLCTSSCTSK
SCHEMBL21411586 0.75 KEAP1 (0.40) AAK1KEAP1NFE2L2CTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339193-B2 CDP protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2022-05-24 US disclosed
US-20210017233-A1 CDP PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11339193-B2 CDP protein secretion inhibitors SEC61G, SEC61A1, SEC61B REN 4067/4885NOS3 4106/4885NOS1 3972/4885
US-20210017233-A1 CDP PROTEIN SECRETION INHIBITORS SEC61G, SEC61A1, SEC61B REN 4067/4885NOS3 4106/4885NOS1 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.